Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate

Ya-Dan Wang; Guo-Hui Cui; Mian Li; Bhuveshwarnath Gowrea; Jia Xia; Yu Hu

Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate

Chin Med J (Engl). 2012 Jul;125(14):2636-7.

Authors

Ya-Dan Wang¹, Guo-Hui Cui, Mian Li, Bhuveshwarnath Gowrea, Jia Xia, Yu Hu

Affiliation

¹ Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.

PMID: 22882953

Abstract

Imatinib mesylate is a molecular targeted agent for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumor. Although imatinib mesylate is not regarded as an immunosuppressive agent, few studies have also shown that it may impair immune response. In this report, we present a case of transient hepatitis B virus (HBV) reactivation during imatinib mesylate treatment for CML.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Benzamides
Hepatitis B virus / pathogenicity*
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / virology*
Male
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*
Virus Replication / drug effects

Substances

Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate